Reference: 38 CFR 4.124a

Sources & Related Guides

What is the VA rating for Soft-Tissue Sarcoma (of Neurogenic Origin)?

Understand Soft-Tissue Sarcoma (of Neurogenic Origin) guidance under DC 8540, a standalone flat 100 percent rating during active treatment or within six months of its cessation, with a disclosed post-treatment residual dispatch. DC 8540 is the last entry under 4.124a's 'Diseases of the Peripheral Nerves' heading despite having no nerve-impairment content of its own, per COND-083/RSCH-090.

What is Soft-Tissue Sarcoma (of Neurogenic Origin)?

38 CFR 4.124a's DC 8540 covers soft-tissue sarcoma of neurogenic origin with a single flat 100 percent rating that continues through active surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment, and continues for six months after that treatment ends. Six months after discontinuance of treatment, if there has been no local recurrence or metastasis, the rating is made on residuals -- a determination RatingScope cannot compute and discloses as a limitation rather than guessing. DC 8540 is textually the last entry under 38 CFR 4.124a's 'Diseases of the Peripheral Nerves' heading, immediately after DC 8730 and immediately before 'The Epilepsies' heading (DC 8910), even though it carries no functional-nerve-impairment content of its own -- the heading's own general incomplete-paralysis and bilateral-factor grading language does not reach it. No public VA DBQ is built to capture this condition's relevant findings; oncology treatment records and pathology or biopsy confirmation are the real evidence source.

Next steps

What would you like to do with Soft-Tissue Sarcoma (of Neurogenic Origin)?

Start AssessmentAnswer condition-scoped questions using documented findings from your records or exam notes.ContinuePercentage GuideSee the published percentage tiers and what changes between them.ContinueSecondary ConditionsSee conditions commonly connected to this one in VA claims.Continue

Save this condition to find it again later. Saved only on this device and browser. Never sent to RatingScope. Lost if you clear browser data or switch devices or browsers.

Start with your question

What are you trying to understand about soft-tissue sarcoma (of neurogenic origin)?

Overview

How VA rates soft-tissue sarcoma of neurogenic origin

38 CFR 4.124a's DC 8540 covers soft-tissue sarcoma of neurogenic origin with a single flat 100 percent rating that continues through active surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment, and continues for six months after that treatment ends. Six months after discontinuance of treatment, if there has been no local recurrence or metastasis, the rating is made on residuals -- a determination RatingScope cannot compute and discloses as a limitation rather than guessing. DC 8540 is textually the last entry under 38 CFR 4.124a's 'Diseases of the Peripheral Nerves' heading, immediately after DC 8730 and immediately before 'The Epilepsies' heading (DC 8910), even though it carries no functional-nerve-impairment content of its own -- the heading's own general incomplete-paralysis and bilateral-factor grading language does not reach it. No public VA DBQ is built to capture this condition's relevant findings; oncology treatment records and pathology or biopsy confirmation are the real evidence source.

This guide is educational only. RatingScope does not diagnose a soft-tissue sarcoma of neurogenic origin, does not infer a confirmed diagnosis, does not determine service connection, and does not predict a VA decision. This hub computes only DC 8540's flat 100 percent rating during active treatment or within six months of its cessation. The post-six-month residual determination is disclosed as a limitation, never computed or guessed. A pending VA rulemaking (RIN 2900-AQ73) proposes adding a new subheading, 'Other Neoplasms of the Neurological System,' directly above DC 8540, but the proposed rule's own text states no other changes are proposed for this diagnostic code; this hub is built on the current, in-force regulatory text, not the proposed rule.

Percentage Guides

Understanding Your Percentage

Select a pathway to see what the published criteria ask about, what records may clarify it, and what should not be assumed.

100%

Highest listed pathway

The 100% level applies to a confirmed soft-tissue sarcoma of neurogenic origin while receiving active surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment, and continues for six months after that treatment ends.

What separates the next level: There is no lower tier under DC 8540. Once treatment has been discontinued for six months or more with no local recurrence or metastasis, DC 8540's own text no longer provides a percentage -- the rating is instead made on whatever residual condition remains, under whichever diagnostic code fits those residuals. RatingScope discloses this as a limitation and does not compute it.

Review CFR criteria, examples, and evidence
Official CFR language
8540 Soft-tissue sarcoma (of neurogenic origin) -- 100. Note: The 100 percent rating will be continued for 6 months following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals.
Qualification explanation
Reached by a confirmed diagnosis of a soft-tissue sarcoma of neurogenic origin together with active treatment, or treatment that ended less than six months ago. This is the only outcome this hub computes.
Examples
Records documenting a confirmed soft-tissue sarcoma of neurogenic origin diagnosis and ongoing or recently concluded (within six months) surgical, radiation, or chemotherapy treatment.
Medical evidence
Oncology treatment records; Pathology or biopsy confirming the neurogenic soft-tissue sarcoma diagnosis; Records documenting treatment type and dates, including any cessation date
Functional impact examples
Currently undergoing chemotherapy, radiation, surgery, or another therapeutic procedure for a diagnosed soft-tissue sarcoma of neurogenic origin.; Treatment ended within the last six months.
Common misconceptions
A soft-tissue sarcoma of neurogenic origin diagnosis does not, by itself, continue at 100 percent indefinitely -- six months after treatment ends, DC 8540's own Note requires the rating to be made on residuals if there has been no local recurrence or metastasis.
Related topics
neurogenic soft-tissue sarcoma diagnosis; active treatment; post-treatment reassessment
Source context
38 CFR 4.124a; 8540; Confirmed via eCFR renderer API, Cornell LII, and govinfo XML, word-for-word match. Appendix A lists DC 8540 as 'Added October 15, 1991'; no substantive revision since found.

Learn

Understand the details behind the criteria

Use these short guides to connect published terms with the records and observations that may clarify them.

After six months post-treatment, DC 8540 dispatches to residuals (not computed)

DC 8540's own Note requires the rating to be made on residuals six months after treatment ends, if there has been no local recurrence or metastasis, under an appropriate diagnostic code for that residual. RatingScope does not compute or guess which diagnostic code or percentage that would be.

  • DC 8540's Note, verbatim: "The 100 percent rating will be continued for 6 months following the cessation of surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure. At this point, if there has been no local recurrence or metastases, the rating will be made on residuals."
  • This is the same open 'rate on residuals' dispatch pattern already used elsewhere in this repository for other malignant-neoplasm and post-treatment codes, including Respiratory Neoplasms' DC 6819 and Arterial Venous Remaining's DC 7123, both already live and both disclosed as a limitation rather than computed.
  • This hub computes only the 100 percent rating that applies during active treatment and within the six-month window after treatment ends. It does not compute, estimate, or guess at the residual rating that would apply after that window closes.

Records to review: Oncology treatment and follow-up records documenting treatment cessation date; Follow-up examination findings confirming no local recurrence or metastasis, once available.

DC 8540 sits under 'Diseases of the Peripheral Nerves,' but has no nerve-impairment content

Under current, in-force law, DC 8540 is textually the last entry under 38 CFR 4.124a's 'Diseases of the Peripheral Nerves' heading, immediately after DC 8730 and immediately before the 'The Epilepsies' heading (DC 8910), even though its own text is entirely oncological and states no nerve-function finding. The heading's general incomplete-paralysis and bilateral-factor grading language does not reach DC 8540.

  • 38 CFR 4.124a's 'Diseases of the Peripheral Nerves' heading groups a long list of nerve-specific diagnostic codes (paralysis, neuritis, and neuralgia findings for named peripheral nerves), each graded by severity of incomplete or complete paralysis. DC 8540 is the final code listed under that heading, placed there by current regulatory text, but its own subject matter is a soft-tissue sarcoma diagnosis and treatment timeline, not a nerve-function finding.
  • The heading's own general introductory note (grading incomplete paralysis as mild, moderate, moderately severe, or severe, and applying the 38 CFR 4.26 bilateral factor) is confined by its own text to nerve-impairment grading. Because DC 8540's own text states no nerve-impairment finding at all, that general note does not reach it. RatingScope does not apply any bilateral-factor logic to DC 8540.
  • A pending VA rulemaking, RIN 2900-AQ73, proposes adding a new subheading, 'Other Neoplasms of the Neurological System,' directly above DC 8540 in a future version of this schedule. The proposed rule's own text states explicitly that no other changes are proposed for DC 8540 itself. This proposal has not been finalized as of this hub's build date. RatingScope builds and rates on the current, in-force regulatory text and will update this hub in a future work order if and when this rule finalizes.

Records to review: .

No standard VA DBQ is built to capture this condition

The Peripheral Nerves DBQ, the closest candidate given DC 8540's schedule placement, is built entirely around nerve-function impairment grading and cannot capture a tumor diagnosis, treatment status, or recurrence/metastasis findings. Oncology treatment records and pathology or biopsy confirmation are the real evidence source for this condition, not a standard DBQ.

  • DC 8540's own text has nothing to do with nerve function: it rates a diagnosis, an active-treatment timeline, and a post-treatment recurrence/metastasis finding. The Peripheral Nerves DBQ's fields (paralysis grade, sensory and motor findings by named nerve) have no place to record any of that.
  • A veteran researching this condition should know that the standard DBQ path does not apply here. The real evidence to gather is oncology treatment records documenting diagnosis and treatment dates, and pathology or biopsy results confirming the diagnosis -- not a nerve-function examination form.
  • This is a genuine sourcing gap in VA's own published DBQ library, not a RatingScope limitation. Confirmed by direct inspection of the Peripheral Nerves DBQ's own field structure during RSCH-090.

Records to review: Oncology treatment records; Pathology or biopsy results confirming the diagnosis.

Evidence

Evidence that may clarify the published criteria

Oncology diagnosis and treatment records

Records confirming a soft-tissue sarcoma of neurogenic origin diagnosis, and documenting the type and dates of any surgical, radiation, chemotherapy, or other therapeutic treatment. These records are the real evidence source for this condition -- no standard VA DBQ is built to capture DC 8540's findings.

A neoplasm diagnosis alone does not establish the 100 percent tier without documented active treatment or a treatment cessation date within the last six months.

Pathology or biopsy results

Confirms the neurogenic soft-tissue sarcoma diagnosis. Since no standard DBQ captures this finding, pathology or biopsy confirmation is the evidence a veteran should gather directly from their treating oncologist.

Do not assume the diagnosis without documented pathology results.

No adequate public DBQ -- oncology records instead

No public VA DBQ is built to capture DC 8540's relevant findings. The Peripheral Nerves DBQ, the closest candidate given DC 8540's schedule placement, is structurally unable to document a tumor diagnosis, treatment status, or recurrence/metastasis findings, since it is built entirely around nerve-function impairment grading. Oncology treatment records and pathology or biopsy confirmation are the real evidence source instead.

A veteran should not expect a Peripheral Nerves DBQ appointment to capture the findings DC 8540 actually requires.

DBQ

Soft-Tissue Sarcoma (Neurogenic Origin) exam findings to look for

No public VA DBQ is built for this condition. The Peripheral Nerves DBQ, the closest candidate given DC 8540's schedule placement, cannot capture a tumor diagnosis, treatment status, or recurrence/metastasis findings -- it is built entirely around nerve-function impairment grading. This section helps veterans identify what oncology treatment and pathology records to gather instead. It does not diagnose a neurogenic soft-tissue sarcoma, decide service connection, or predict a VA decision.

  • Whether a soft-tissue sarcoma of neurogenic origin is documented
  • Whether surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment is active or has ended, and when it ended
  • Whether there has been local recurrence or metastasis once the six-month post-treatment window is reached

Terminology

Plain-English terms

Soft-tissue sarcoma of neurogenic origin (DC 8540)

Rated 100 percent while receiving active treatment and for six months after treatment ends. After that, if there has been no local recurrence or metastasis, the rating is made on residuals.

The only outcome this hub computes is the flat 100 percent tier during or within six months of active treatment.

DC 8540's peripheral-nerve heading placement

This placement governs today. The heading's general incomplete-paralysis and bilateral-factor grading language does not reach DC 8540, since DC 8540's own text states no nerve-impairment finding.

RatingScope does not apply any bilateral-factor logic to DC 8540. A pending rule (RIN 2900-AQ73) would relabel the heading directly above DC 8540, with no change to DC 8540's own criteria.

TDIU

Even if the schedular rating for Soft-Tissue Sarcoma (of Neurogenic Origin) does not reach 100 percent, TDIU may still provide a pathway to compensation at the 100 percent rate, based on unemployability from this and/or other service-connected disabilities combined.

A lower schedular percentage does not by itself foreclose TDIU eligibility -- this hub computes only the schedular percentage for this specific condition and does not determine TDIU eligibility.

Employment history; vocational impact documentation; occupational impairment

Common Questions

Questions veterans commonly ask

How does VA rate soft-tissue sarcoma of neurogenic origin?

DC 8540 rates a confirmed soft-tissue sarcoma of neurogenic origin at a flat 100 percent while receiving active surgical, X-ray, antineoplastic chemotherapy, or other therapeutic treatment, and for six months after that treatment ends. Six months after treatment ends, if there has been no local recurrence or metastasis, DC 8540's own Note requires the rating to be made on residuals.

What happens after treatment ends?

The 100 percent rating continues for six months after treatment ends. After that six-month window, if there has been no local recurrence or metastasis, DC 8540's Note requires the rating to be made on residuals under an appropriate diagnostic code. RatingScope does not compute or guess at that residual rating.

Why is DC 8540 listed under peripheral nerves if it has no nerve findings?

Under current law, DC 8540 is textually the last entry under 38 CFR 4.124a's 'Diseases of the Peripheral Nerves' heading, immediately after DC 8730 and immediately before 'The Epilepsies' heading, even though its own text is entirely oncological. The heading's general nerve-impairment grading language, including the bilateral factor, does not reach DC 8540. A pending rule (RIN 2900-AQ73) would relabel the heading directly above DC 8540, with no change to DC 8540's own criteria.

What evidence is helpful, and why doesn't a standard DBQ cover this?

No public VA DBQ is built to capture DC 8540's relevant findings. The Peripheral Nerves DBQ, the closest candidate given DC 8540's schedule placement, is built entirely around nerve-function impairment grading and cannot document a tumor diagnosis, treatment status, or recurrence/metastasis findings. Oncology treatment records and pathology or biopsy confirmation are the real evidence source a veteran should gather instead.

If my schedular rating for Soft-Tissue Sarcoma (of Neurogenic Origin) is below 100%, can I still be compensated at the 100% rate?

Possibly, through TDIU (Total Disability rating based on Individual Unemployability, 38 CFR 4.16) -- a separate pathway to 100 percent compensation based on unemployability, from this and/or other service-connected disabilities combined, independent of whether the schedular rating itself reaches 100 percent. This hub computes only the schedular percentage and does not determine TDIU eligibility.

Preparation

What to have nearby

  • Confirmed neurogenic soft-tissue sarcoma diagnosis

    Pathology or biopsy results establish that DC 8540 applies.

  • Treatment status and cessation date

    DC 8540's 100 percent tier depends on whether treatment is active or ended within the last six months.

  • Recurrence or metastasis findings, if treatment has concluded

    Needed for the residual determination this hub does not compute once the six-month post-treatment window closes.

Ready when you are

Soft-Tissue Sarcoma (Neurogenic Origin) record comparison

RatingScope's Soft-Tissue Sarcoma (Neurogenic Origin) assessment computes only DC 8540's flat 100 percent rating during active treatment or within six months of its cessation. It does not compute the post-six-month residual rating, which is an open dispatch to a residual diagnostic code determined once local recurrence or metastasis has been ruled out.

Informational guidance only. RatingScope does not predict, decide, or guarantee VA outcomes.

Try the Soft-Tissue Sarcoma (Neurogenic Origin) record comparison

Learn More

Continue Understanding

38 CFR 4.124a, DC 8540

Primary source for DC 8540's current text.

Open resource

Federal Register NPRM, RIN 2900-AQ73 (89 FR 88917, Nov. 12, 2024)

Primary source for the pending, not-yet-final proposal to add a new subheading directly above DC 8540. The proposed rule's own text states no other changes are proposed for DC 8540.

Open resource

Respiratory Neoplasms guide

Shares the identical flat-100-percent-plus-disclosed-residual-dispatch structure with this hub.

Open resource

Aneurysm, Arteriovenous Fistula, Angioneurotic Edema, Erythromelalgia, and Vascular Sarcoma guide

Shares the identical flat-100-percent-plus-disclosed-residual-dispatch structure with this hub (DC 7123).

Open resource

38 CFR 4.16 - Total disability ratings for compensation based on unemployability (TDIU)

Official source for TDIU, a separate pathway to 100 percent compensation based on unemployability, independent of the schedular percentage. This hub does not determine TDIU eligibility.

Open resource

Secondary conditions

Conditions commonly connected to Soft-Tissue Sarcoma (of Neurogenic Origin)

No commonly documented secondary connections are tracked for Soft-Tissue Sarcoma (of Neurogenic Origin) yet.

Keep going

Related Tools

Compare a percentage level and combined-rating math, or review evidence context.

See all tools

Percentage Guide

See what each percentage level means for your condition, then use the whole-person calculator to combine more than one rating.

Open Percentage Guide

Evidence Categories

Understand common evidence categories and what they can clarify without treating them as a checklist.

Review evidence categories